MU
| Title | Published in | Access level | OA Policy | Year | Views | Downloads | |
|---|---|---|---|---|---|---|---|
| Overall survival of recurrent/metastatic head & neck squamous cell carcinoma patients progressing after ≥ 1 line of systemic therapy, treated with MVX-ONCO-1, a novel, first in class cell encapsulation-based immunotherapy : results of SAKK 11/16, a phase IIa trial | Experimental hematology & oncology | 2025 | 19 | 19 | |||
| A First-in-Human Phase I Clinical Study with MVX-ONCO-1, a Personalized Active Immunotherapy, in Patients with Advanced Solid Tumors | Cancer research communications | 2024 | 101 | 117 | |||
| LBA46 SAKK 11/16, a phase IIa trial evaluating overall survival (OS) for recurrent/metastatic Head & neck squamous cell carcinoma (RMHNSCC) patients (pts) progressing after ≥ 1 line of systemic therapy, treated with MVX-ONCO-1, a novel, first in class cell encapsulation-based immunotherapy | ESMO Congress 2023 | 2023 | 112 | 50 | |||
| Engineering a versatile and retrievable cell macroencapsulation device for the delivery of therapeutic proteins | iScience | 2023 | 95 | 37 | |||
| Sustained delivery of low-dose anti-CTLA-4 by genetically engineered encapsulated cells to the tumor microenvironment drives tumor response and prolongs survival in a colorectal cancer model | AACR Annual Meeting 2023 | 2023 | 68 | 81 | |||
| Personalized immunotherapy with encapsulated cell technology : Feasibility, safety and efficacy results from the first-in-human clinical trial in advanced relapsing solid tumors | ESMO Congress 2022 | 2022 | 80 | 100 | |||
| Immortalised human myoblast cell lines for the delivery of therapeutic proteins using encapsulated cell technology | Molecular therapy. Methods & clinical development | 2022 | 237 | 134 |
